This page contains the Nonprescription Drugs Advisory Committee Roster, which lists the current members and the current number of vacancies for the committee.
Similar Posts
FDA in Brief: FDA warns company for putting consumers at risk through distribution of non-compliant and misbranded drug ingredients
FDA issued a warning letter to Professional Compounding Centers of America Inc. (PCCA) for receiving and distributing adulterated and misbranded active pharmaceutical ingredients (APIs).Find Information about a Drug
Information on FDA-approved drugs released for sale on the market, such as dosage, side effects, and disposal methodsAzurity Pharmaceuticals, Inc. – 656489 – 09/20/2024
CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New DrugRecently Issued Guidance Documents
This page lists Recently Issued CBER and Cross-Center Guidance Documents.Completed PDUFA VII Deliverables
Since the passage of the Prescription Drug User Fee Act (PDUFA) in 1992, user fees have played an important role in expediting the drug approval process while ensuring their safety and efficacy. PDUFA must be reauthorized every five years, and in September 2022, the President signed into law the sixEugia Pharma Specialities Limited – 2/6/2026
Eugia Pharma Specialities Limited – 2/6/2026. Country: India. Record Type: 483